Playback speed
10 seconds
SGO 2022 on Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: A Cost-Effectiveness Analysis
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
David Barrington
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
David Barrington
239 views
April 7, 2022
Comments 0
Login to view comments.
Click here to Login